The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: a systematic literature review

Research output: Contribution to journalArticle

Standard

Harvard

APA

Vancouver

Author

Bibtex

@article{d9c70230a7ce411d8aec80bf1f9171a6,
title = "The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: a systematic literature review",
abstract = "Introduction: A range of impulse control disorders have been identified as possible behavioural effects of brain dopamine replacement therapy (DRT) in patients with Parkinson's disease (PD). Among the behavioural problems associated with dysregulation of dopaminergic pathways underlying reward processing, hypersexuality carries significant social and legal repercussions, in addition to embarrassment for the patient with PD and his/her family. The present article evaluates the prevalence and characteristics of hypersexuality in the context of PD, focusing on the best available evidence.Methods:We conducted a systematic literature review according to the Prisma guidelines on large-scale epidemiological studies (n > 250) assessing hypersexuality in patients with PD treated with DRT.Results: Our systematic literature review identified 10 relevant studies characterised by medium–to-large sample sizes (n = 268-3090). Average lifetime prevalence of hypersexuality in patients with PD on DRT was found to be 2.7% (7.4% in patients on dopamine agonists). In general, hypersexuality was associated with male gender and higher doses of dopamine agonists. Other clinically relevant associations included younger age, earlier PD onset and history of behavioural symptoms prior to dopamine agonist use.Conclusion: Hypersexuality is not rare in patients with PD treated with DRT, particularly in those on dopamine agonists. These findings indicate that PD specialists should regularly screen and monitor for hypersexuality, paying particular attention to younger male patients, with an early PD onset and previous history of behavioural problems.",
keywords = "Parkinson's disease, Hypersexuality, Impulse control disorders, Dopamine replacement therapy, Levodopa, Dopamine agonists",
author = "Shivanee Nakum and Cavanna, {Andrea E.}",
year = "2016",
month = apr
doi = "10.1016/j.parkreldis.2016.02.017",
language = "English",
volume = "25",
pages = "10--16",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy

T2 - a systematic literature review

AU - Nakum, Shivanee

AU - Cavanna, Andrea E.

PY - 2016/4

Y1 - 2016/4

N2 - Introduction: A range of impulse control disorders have been identified as possible behavioural effects of brain dopamine replacement therapy (DRT) in patients with Parkinson's disease (PD). Among the behavioural problems associated with dysregulation of dopaminergic pathways underlying reward processing, hypersexuality carries significant social and legal repercussions, in addition to embarrassment for the patient with PD and his/her family. The present article evaluates the prevalence and characteristics of hypersexuality in the context of PD, focusing on the best available evidence.Methods:We conducted a systematic literature review according to the Prisma guidelines on large-scale epidemiological studies (n > 250) assessing hypersexuality in patients with PD treated with DRT.Results: Our systematic literature review identified 10 relevant studies characterised by medium–to-large sample sizes (n = 268-3090). Average lifetime prevalence of hypersexuality in patients with PD on DRT was found to be 2.7% (7.4% in patients on dopamine agonists). In general, hypersexuality was associated with male gender and higher doses of dopamine agonists. Other clinically relevant associations included younger age, earlier PD onset and history of behavioural symptoms prior to dopamine agonist use.Conclusion: Hypersexuality is not rare in patients with PD treated with DRT, particularly in those on dopamine agonists. These findings indicate that PD specialists should regularly screen and monitor for hypersexuality, paying particular attention to younger male patients, with an early PD onset and previous history of behavioural problems.

AB - Introduction: A range of impulse control disorders have been identified as possible behavioural effects of brain dopamine replacement therapy (DRT) in patients with Parkinson's disease (PD). Among the behavioural problems associated with dysregulation of dopaminergic pathways underlying reward processing, hypersexuality carries significant social and legal repercussions, in addition to embarrassment for the patient with PD and his/her family. The present article evaluates the prevalence and characteristics of hypersexuality in the context of PD, focusing on the best available evidence.Methods:We conducted a systematic literature review according to the Prisma guidelines on large-scale epidemiological studies (n > 250) assessing hypersexuality in patients with PD treated with DRT.Results: Our systematic literature review identified 10 relevant studies characterised by medium–to-large sample sizes (n = 268-3090). Average lifetime prevalence of hypersexuality in patients with PD on DRT was found to be 2.7% (7.4% in patients on dopamine agonists). In general, hypersexuality was associated with male gender and higher doses of dopamine agonists. Other clinically relevant associations included younger age, earlier PD onset and history of behavioural symptoms prior to dopamine agonist use.Conclusion: Hypersexuality is not rare in patients with PD treated with DRT, particularly in those on dopamine agonists. These findings indicate that PD specialists should regularly screen and monitor for hypersexuality, paying particular attention to younger male patients, with an early PD onset and previous history of behavioural problems.

KW - Parkinson's disease

KW - Hypersexuality

KW - Impulse control disorders

KW - Dopamine replacement therapy

KW - Levodopa

KW - Dopamine agonists

U2 - 10.1016/j.parkreldis.2016.02.017

DO - 10.1016/j.parkreldis.2016.02.017

M3 - Article

VL - 25

SP - 10

EP - 16

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -